Olgu Sunumu

Skin necrosis: An uncommon side effect of warfarin therapy

Cilt: 58 Sayı: 2 28 Haziran 2019
PDF İndir
TR EN

Skin necrosis: An uncommon side effect of warfarin therapy

Abstract

Warfarin is commonly used in the treatment and prevention of thromboembolic events. However, it is known to undesirably cause hypercoagulable conditions, including warfarin-induced skin necrosis (WISN). This report describes a 70-year-old man presented with an extensive WISN while an inpatient for treatment of a left deep femoral vein thrombosis. He had a background of colon adenocarcinoma and multiple metastatic foci in the liver

Keywords

Kaynakça

  1. Nazarian RM, Van Cott EM, Zembowicz A, Duncan LM. Warfarin-induced skin necrosis. J Am Acad Dermatol 2009;61(2):325-32.
  2. Kakagia DD, Papanas N, Karadimas E, Polychronidis A. Warfarin-induced skin necrosis. Ann Dermatol 2014;26(1):96-8.
  3. Menon N, Sarode R, Zia A. Rivaroxaban dose adjustment using thrombin generation in severe congenital protein C deficiency and warfarin-induced skin necrosis. Blood Adv 2018;2(2):142-5.
  4. Chan YC, Valenti D, Mansfield AO, Stansby G. Warfarin induced skin necrosis. Br J Surg 2000;87(3):266-272.
  5. Hasegawa H. Clinical assessment of warfarin therapy in patients with maintenance dialysis-clinical efficacy, risks and development of calciphylaxis. Ann Vasc Dis 2017;10(3):170-7.
  6. Hamada T, Miyake T, Otsuka M, Iwatsuki K. Warfarin-induced skin necrosis accompanied by aggravation of vasculitis in a patient with cutaneous arteritis. Int J Dermatol 2017;56(7):779-81.

Ayrıntılar

Birincil Dil

İngilizce

Konular

Sağlık Kurumları Yönetimi

Bölüm

Olgu Sunumu

Yazarlar

Serkan Demirkan
0000-0002-3960-3891
Türkiye

Yayımlanma Tarihi

28 Haziran 2019

Gönderilme Tarihi

31 Ocak 2018

Kabul Tarihi

9 Nisan 2018

Yayımlandığı Sayı

Yıl 2019 Cilt: 58 Sayı: 2

Kaynak Göster

Vancouver
1.Tuba Devrim, Serkan Demirkan. Skin necrosis: An uncommon side effect of warfarin therapy. ETD. 01 Haziran 2019;58(2):190-1. doi:10.19161/etd.417314

Ege Tıp Dergisi, makalelerin Atıf-Gayri Ticari-Aynı Lisansla Paylaş 4.0 Uluslararası (CC BY-NC-SA 4.0) lisansına uygun bir şekilde paylaşılmasına izin verir.